GSK/Theravance start asthma drug trials
UK drug major GlaxoSmithKline and USA-based biopharmaceutical company Theravance say they have initiated Phase IIb trials of the inhaled corticosteroid, GW685698, and the long-acting beta agonist, GW642444. The program is designed to produce dose optimization data for the two compounds, which are being developed as a next-generation combination therapy for asthma.
The two studies form part of the HORIZON program, which is currently enrolling sufferers of persistent asthma. These will recruit around 2,400 patients worldwide, and will both utilize a new inhalation device that has been developed by the two firms. An additional assessment of GW642444 in chronic obstructive pulmonary disease is due to begin in the next few months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze